HCPCS Level II · Outpatient PPS (temporary codes)
C9073Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Terminated 03/31/2021
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About C9073
C9073 is an HCPCS Level II code in the C series (outpatient PPS (temporary codes)), describing brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.
It was added to HCPCS effective 01/01/2021, and its current record took effect 04/01/2021.
It was terminated on 03/31/2021 and can't be billed for later dates of service.
Its Medicare coverage code is "D", meaning special Medicare coverage instructions apply.
Details
- Short description
- Brexucabtagene autoleucel ca
- Date added
- 01/01/2021
- Action effective
- 04/01/2021
- Termination date
- 03/31/2021
- BETOS
- O1E
Related C90xx codes
Common questions about C9073
Is HCPCS C9073 still valid?
- No. C9073 was terminated on 03/31/2021.
Does Medicare cover C9073?
- Its coverage code is "D": special Medicare coverage instructions apply. Check the local coverage determination for your region.